9 results on '"Bennett, CM"'
Search Results
2. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review.
- Author
-
Bennett CM, Guo M, and Dharmage SC
- Published
- 2007
- Full Text
- View/download PDF
3. Random amplified polymorphic DNA analysis reveals no clear link between Staphylococcus epidermidis and acute mastitis.
- Author
-
Cullinane M, Scofield L, Murray GL, Payne MS, Bennett CM, Garland SM, and Amir LH
- Subjects
- Animals, Case-Control Studies, Cattle, DNA, Female, Humans, Random Amplified Polymorphic DNA Technique, Staphylococcus genetics, Mastitis, Bovine microbiology, Staphylococcus epidermidis genetics
- Abstract
Mastitis is commonly experienced by breastfeeding women. While Staphylococcus aureus is usually implicated in infectious mastitis, coagulase-negative staphylococci (CoNS) are a possible alternative pathogen. This case-control study examined the role of CoNS in mastitis using isolates cultured from breast milk of 20 women with mastitis and 16 women without mastitis. Gene sequencing determined bacterial species, and random amplified polymorphic DNA (RAPD) analysis investigated strain-level variation. The majority of CoNS isolates were Staphylococcus epidermidis (182/199; 91%). RAPD analysis identified 33 unique S. epidermidis profiles, with no specific profile associated with mastitis cases., (© 2022 The Authors. Australian and New Zealand Journal of Obstetrics and Gynaecology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Obstetricians and Gynaecologists.)
- Published
- 2022
- Full Text
- View/download PDF
4. Fatigue is common in paediatric immune thrombocytopenia and improves with second-line treatments.
- Author
-
White MH and Bennett CM
- Subjects
- Adolescent, Autoimmunity, Child, Fatigue etiology, Fatigue therapy, Humans, Purpura, Thrombocytopenic, Idiopathic drug therapy, Thrombocytopenia therapy
- Published
- 2020
- Full Text
- View/download PDF
5. Pollen exposure at birth and adolescent lung function, and modification by residential greenness.
- Author
-
Lambert KA, Lodge C, Lowe AJ, Prendergast LA, Thomas PS, Bennett CM, Abramson MJ, Dharmage SC, and Erbas B
- Subjects
- Adolescent, Allergens immunology, Child, Cohort Studies, Female, Humans, Infant, Newborn, Lung pathology, Male, Poaceae adverse effects, Respiratory Function Tests, Rhinitis, Allergic, Seasonal epidemiology, Environment, Environmental Exposure, Lung immunology, Lung physiopathology, Pollen immunology, Rhinitis, Allergic, Seasonal diagnosis, Rhinitis, Allergic, Seasonal etiology
- Abstract
Background: Exposure to high levels of pollen in infancy is a risk factor for allergic respiratory diseases in later childhood, but effects on lung function are not fully understood. We aim to examine associations between grass pollen exposure in the first months of life and lung function at 12 and 18 years, and explore potential modification., Methods: Using the Melbourne Atopy Cohort Study, a birth cohort of children with a family history of allergic diseases, we modeled the association between cumulative grass pollen exposure up to 3 months after birth, on FEV
1 , FVC, and FEV1 /FVC ratio at 12 and 18 years. We also assessed modifying effects of residential greenness levels (derived from satellite imagery), asthma, and early life sensitization to ryegrass., Results: Grass pollen exposure in the first 7 days was associated with a reduction in FEV1 (-15.5 mL; 95% CI: -27.6, -3.3 per doubling of pollen count) and FVC (-20.8 mL; -35.4, -6.1) at 12 years, but not at 18 years. Increase in cumulative grass pollen exposure up to 3 months was negatively associated with FVC at 12 and 18. Exposure to high residential greenness modified the association at 18 years., Conclusion: Early exposure to grass pollen was associated with decreased lung function in children and adolescents. Targeted interventions for pollen avoidance strategies that take into account local topography could be implemented alongside other clinical interventions such as immunotherapy., (© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF
6. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.
- Author
-
Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, and Despotovic JM
- Subjects
- Adolescent, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Infant, Male, Platelet Count, Prospective Studies, Survival Rate, Time Factors, Purpura, Thrombocytopenic, Idiopathic blood, Purpura, Thrombocytopenic, Idiopathic drug therapy, Quality of Life, Receptors, Fc administration & dosage, Recombinant Fusion Proteins administration & dosage, Rituximab administration & dosage, Thrombopoietin administration & dosage
- Abstract
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated thrombocytopenia and hemorrhagic risk. While many children with ITP can be safely observed, treatments are often needed for various reasons, including to decrease bleeding, or to improve health related quality of life (HRQoL). There are a number of available second-line treatments, including rituximab, thrombopoietin-receptor agonists, oral immunosuppressive agents, and splenectomy, but data comparing treatment outcomes are lacking. ICON1 is a prospective, multi-center, observational study of 120 children starting second-line treatments for ITP designed to compare treatment outcomes including platelet count, bleeding, and HRQoL utilizing the Kids ITP Tool (KIT). While all treatments resulted in increased platelet counts, romiplostim had the most pronounced effect at 6 months (P = .04). Only patients on romiplostim and rituximab had a significant reduction in both skin-related (84% to 48%, P = .01 and 81% to 43%, P = .004) and non-skin-related bleeding symptoms (58% to 14%, P = .0001 and 54% to 17%, P = .0006) after 1 month of treatment. HRQoL significantly improved on all treatments. However, only patients treated with eltrombopag had a median improvement in KIT scores at 1 month that met the minimal important difference (MID). Bleeding, platelet count, and HRQoL improved in each treatment group, but the extent and timing of the effect varied among treatments. These results are hypothesis generating and help to improve our understanding of the effect of each treatment on specific patient outcomes. Combined with future randomized trials, these findings will help clinicians select the optimal second-line treatment for an individual child with ITP., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
7. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.
- Author
-
Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ, Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, and Lambert MP
- Subjects
- Child, Decision Making, Female, Humans, Immunosuppressive Agents therapeutic use, Male, Physicians psychology, Rituximab therapeutic use, Splenectomy, Clinical Decision-Making, Purpura, Thrombocytopenic, Idiopathic drug therapy
- Abstract
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder which presents with isolated thrombocytopenia and risk of hemorrhage. While most children with ITP promptly recover with or without drug therapy, ITP is persistent or chronic in others. When needed, how to select second-line therapies is not clear. ICON1, conducted within the Pediatric ITP Consortium of North America (ICON), is a prospective, observational, longitudinal cohort study of 120 children from 21 centers starting second-line treatments for ITP which examined treatment decisions. Treating physicians reported reasons for selecting therapies, ranking the top three. In a propensity weighted model, the most important factors were patient/parental preference (53%) and treatment-related factors: side effect profile (58%), long-term toxicity (54%), ease of administration (46%), possibility of remission (45%), and perceived efficacy (30%). Physician, health system, and clinical factors rarely influenced decision-making. Patient/parent preferences were selected as reasons more often in chronic ITP (85.7%) than in newly diagnosed (0%) or persistent ITP (14.3%, P = .003). Splenectomy and rituximab were chosen for the possibility of inducing long-term remission (P < .001). Oral agents, such as eltrombopag and immunosuppressants, were chosen for ease of administration and expected adherence (P < .001). Physicians chose rituximab in patients with lower expected adherence (P = .017). Treatment choice showed some physician and treatment center bias. This study illustrates the complexity and many factors involved in decision-making in selecting second-line ITP treatments, given the absence of comparative trials. It highlights shared decision-making and the need for well-conducted, comparative effectiveness studies to allow for informed discussion between patients and clinicians., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
8. Detection of Candida spp. in the vagina of a cohort of nulliparous pregnant women by culture and molecular methods: Is there an association between maternal vaginal and infant oral colonisation?
- Author
-
Payne MS, Cullinane M, Garland SM, Tabrizi SN, Donath SM, Bennett CM, and Amir LH
- Subjects
- Candida albicans genetics, Candida glabrata genetics, Candidiasis, Oral microbiology, Candidiasis, Vulvovaginal microbiology, Carrier State microbiology, Culture Techniques, DNA, Fungal analysis, Female, Humans, Infant, Newborn, Mouth microbiology, Mycology methods, Pregnancy, Pregnancy Complications, Infectious microbiology, Real-Time Polymerase Chain Reaction, Vagina microbiology, Candida albicans isolation & purification, Candida glabrata isolation & purification, Candidiasis, Oral diagnosis, Candidiasis, Vulvovaginal diagnosis, Candidiasis, Vulvovaginal transmission, Carrier State diagnosis, Infectious Disease Transmission, Vertical, Parity, Pregnancy Complications, Infectious diagnosis
- Abstract
Background: Most studies describing vaginal Candida spp. in pregnancy focus on symptomatic vaginitis, rather than asymptomatic colonisation, and solely utilise microbiological culture. The extent to which asymptomatic vaginal carriage may represent a reservoir for infant oral colonisation has been highly debated., Materials and Methods: This study formed part of the Candida and Staphylococcus Transmission Longitudinal Evaluation (CASTLE) study, in Melbourne, Australia, from 2009 to 2011 and used culture and molecular methods to examine vaginal swabs collected late in the third trimester of pregnancy for Candida spp. Oral swabs from infants were also examined using culture methods., Results: Overall, 80 of 356 (22%) women were positive for Candida spp; the majority being Candida albicans (83%). Candida glabrata and other Candida spp. were also identified, but in much lower numbers. Molecular analysis identified numerous positive samples not detected by culture, including 13 cases of C. albicans. In addition, some positive samples only recorded to genus level by culture were accurately identified as either C. albicans or C. glabrata following molecular analyses. Eighteen infants recorded positive Candida spp. cultures, predominantly C. albicans. However, there were only four (25%) mother/infant dyads where C. albicans was detected., Conclusions: This study provides valuable data on asymptomatic colonisation rates of Candida spp. within an asymptomatic population of women late in pregnancy. The utilisation of molecular methods improved the rate of detection and provided a more accurate means for identification of non-albicans Candida spp. The low mother/infant colonisation rate suggests that non-maternal sources are likely involved in determining infant oral colonisation status., (© 2015 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.)
- Published
- 2016
- Full Text
- View/download PDF
9. Female monozygotic twins discordant for hemophilia A due to nonrandom X-chromosome inactivation.
- Author
-
Bennett CM, Boye E, and Neufeld EJ
- Subjects
- DNA Mutational Analysis, Factor VIII genetics, Female, Genetic Linkage, Genetic Markers, Humans, Mutation, Pedigree, Diseases in Twins genetics, Dosage Compensation, Genetic, Hemophilia A genetics, Twins, Monozygotic genetics, X Chromosome Inactivation
- Abstract
We describe monozygotic female twins discordant for hemophilia A, born to a carrier mother and normal father. Affected twin A presented at age 1 year with excessive bruising and factor VIII procoagulant activity (FVIII:C) of less than 1% of normal. Twin B is an asymptomatic carrier with FVIII:C level of 42%. Peripheral blood DNA was tested for X-chromosome inactivation (methylation) patterns of the X-linked human androgen receptor gene, comparing the twins' patterns to parental. Twin A showed nonrandom inactivation skewed toward the paternal X, whereas twin B showed random X-inactivation. This is the first reported case of discordance for hemophilia A between female monozygotic twins., (Copyright 2008 Wiley-Liss, Inc.)
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.